dendritic cell vaccine therapy for Cancer

Phase-Based Progress Estimates
University of California at Los Angeles (UCLA ), Los Angeles, CA
Cancer+1 More
dendritic cell vaccine therapy - Biological
Any Age
All Sexes
What conditions do you have?

Study Summary

This study is evaluating whether a vaccine and a genetic therapy can be used together to treat cancer.

See full description

Eligible Conditions

  • Cancer
  • Neoplasms, Malignant

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

This trial is evaluating whether dendritic cell vaccine therapy will improve 1 primary outcome and 2 secondary outcomes in patients with Cancer. Measurement will happen over the course of Up to 40 days.

Day +90
Clinical response
Up to 40 days
NY-ESO-1 TCR transgenic cell tumor trafficking
Up to 6 years
NY-ESO-1 TCR transgenic cell persistence, quantitated in PBMC samples

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

Treatment (gene and vaccine therapy)
1 of 1
Experimental Treatment

This trial requires 6 total participants across 1 different treatment group

This trial involves a single treatment. Dendritic Cell Vaccine Therapy is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

Treatment (gene and vaccine therapy)CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on days -5 to -4 and fludarabine phosphate IV over 30 minutes on days -4 to -1. TRANSPLANT: Patients receive NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL IV on day 0. Patients also receive NY-ESO-1 (157-165) peptide pulsed dendritic cell vaccine therapy ID on days 1, 14, and 30 and aldesleukin SC BID on days 1-14. Patients may receive 3 additional doses of NY-ESO-1 (157-165) peptide pulsed dendritic cell vaccine therapy after day 90.
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
dendritic cell vaccine therapy
Completed Early Phase 1
fludeoxyglucose F 18
Completed Phase 3
FDA approved
positron emission tomography
Completed Phase 2
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 6 years
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly up to 6 years for reporting.

Closest Location

University of California at Los Angeles (UCLA ) - Los Angeles, CA

Eligibility Criteria

This trial is for patients born any sex of any age. There are 10 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Cancers that have spread to other parts of the body and that cannot be cured with currently available treatments. show original
At least 1 lesion that can be biopsied without having to go to the hospital; this should be a cutaneous or palpable metastatic site or a deeper site accessible by image-guided biopsy that is deemed safe to access by the treating physicians and interventional radiologists show original
The study found that patients with a life expectancy of more than three months were likely to be assessed by a study physician. show original
For patients with skin metastases, lesions selected as non-completely biopsied target lesion(s) will be accurately measured and recorded by color photography with a ruler to document the size of the target lesion(s). show original
Meeting the criteria for a measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST). show original
The study found that the HLA-A*0201 allele was more prevalent in the molecular subtype A1 compared to the subtype A2. show original
You must be at least 16 years old to be eligible for this program. show original
No need to worry about any prior treatments you have had. show original
ECOG performance status is either 0 or 1. show original
The tumor cells were positive for NY-ESO-1 expression by immunohistochemistry (IHC) using commonly available NY-ESO-1 antibodies. show original

Patient Q&A Section

What causes cancer?

"Cancer has at least two causes: epigenetic changes in genes causing them to turn on and tumor suppressive genes that stop cells from dividing when they are needed. In addition, it is also likely that tumor cells are unable to replicate at the same rate as usual cells as a result of the metabolic changes needed for cancer growth." - Anonymous Online Contributor

Unverified Answer

What are common treatments for cancer?

"Rarely is a cure for cancer achievable; a cure for most cancers is not available. It is very important for the health-care provider to remember the cure is not always achievable, and to recommend the most appropriate treatment. A variety of treatment options is available for most cancers and patients have the choice to take medications, receive support from a variety of types of support, visit health-care professionals, receive informational materials, and engage in discussions with other patients. The patient's personal style is not a relevant factor in determining treatment options for cancer patients. Treatment options for cancer may include: surgery, cryotherapy, radiation therapy, chemotherapy, hormonal therapy or other types of cancer treatment." - Anonymous Online Contributor

Unverified Answer

Can cancer be cured?

"With the knowledge currently available and our present understanding of the biology of cancer, the majority of patients diagnosed today should have the opportunity to potentially be cured of their cancer. In patients who have stage three disease or less, the majority of which are curable, it is important to make sure that they have complete surgical removal of all cancer with the best possible histologic characterization. However, in patients with stage two or four cancer and/or patients with N3 disease, surgical staging procedures fail to define the extent of the cancer and therefore will not determine the cure rate. We need to further our research and hopefully someday obtain better understanding of tumor biology." - Anonymous Online Contributor

Unverified Answer

What is cancer?

"Many people have faced cancer, and there are many different types which may be related to a range of different symptoms and signs. Some cancer types will occur in specific age groups, while others will not. Also, the signs and symptoms can depend upon where the cancer has originated in the body and how much of the lining covering the cancer has been torn away or removed. It has long been recognized that not all cancer patients show consistent symptoms or signs across their disease trajectory. This article describes a hypothetical case which aims to show how different cancer types may manifest in different ways over time, but also how the patient may still be able to recognize typical symptomatology as they go along." - Anonymous Online Contributor

Unverified Answer

How many people get cancer a year in the United States?

"In 2000, 11,847 adults had cancer diagnosed in the body systems. This is a rate of new illness of approximately 39 people per 100,000 a year. Of these cases, approximately 38% were breast cancer (18,150); 40% colorectal cancer (18,060); and 19% other malignant neoplasms (4,770). Of those with breast cancer, about 12% are new cases of breast cancer. Of those with colorectal cancer, about 28% are new cases of colorectal cancer. Of those with other malignant neoplasms, about 9% are new, previously unreported cases." - Anonymous Online Contributor

Unverified Answer

What are the signs of cancer?

"Patients with cancer are at risk of anemia and vitamin deficiencies due to the cancer process. Cancer treatments can also lead to bruising and painful mouth sores. Other signs of cancer include a fast, irregular pulse, swollen lymph nodes, poor appetite with a weight loss, vomiting or diarrhea, weakness and fever." - Anonymous Online Contributor

Unverified Answer

What does dendritic cell vaccine therapy usually treat?

"Our patients generally presented with metastatic or recurrent squamous cell carcinoma of the head and neck. Patients typically received two or more cycles of dendritic cell vaccine therapy from an average of 2 to 3 weeks before they presented. The patients were then treated with conventional therapies after relapse or metastatic presentation. Survival analysis showed that patients who were treated early after diagnosis had an increased chance of local or regional recurrence-free survival. The lack of systemic immune response was found to correlate with the absence of local or regional disease-free survival." - Anonymous Online Contributor

Unverified Answer

What are the common side effects of dendritic cell vaccine therapy?

"Clinicians should anticipate that the use of this vaccine will increase the risk of injection site reactions (ISRs) and that these reactions will be similar to those seen with other vaccines as well as those seen in natural infections of viral diseases." - Anonymous Online Contributor

Unverified Answer

How serious can cancer be?

"Serious and unpredictable. I will be very careful to warn patients because if they know about my cancer they might take the news more seriously. I have had to be careful about doctors to not give them bad news because I have gotten fired from at least a dozen doctors. If you are going to go for any test that looks suspicious then see your doctor and tell him or her about the symptoms, the tests and if possible about the possible consequences of the treatment. Make sure the doctor can explain it to you clearly and not use euphemisms or jargon that your layman cannot understand. Cancer is not a joke at all." - Anonymous Online Contributor

Unverified Answer

How does dendritic cell vaccine therapy work?

"We found that adoptive transfer of immune cell clones that specifically recognize antigens from tumors will be very effective against cancer and have the potential to be a new treatment for cancer patients." - Anonymous Online Contributor

Unverified Answer

What is the average age someone gets cancer?

"Cancer presents with peak incidence when people are aged 64 years or older, but the average overall age at diagnosis is 60 years. The pattern varies by site, reflecting differences in cancer predisposition and latency. This pattern of incidence underscores the importance of preventive activities at both primary and secondary prevention levels." - Anonymous Online Contributor

Unverified Answer

Is dendritic cell vaccine therapy safe for people?

"DC vaccination seems to be safe in people. The side effects are very mild and short lived. Vaccination with DCs has advantages over DCs in the use of vaccines because when the human body manufactures its own DCs in response to vaccines, this happens more quickly than natural generation of DCs, and only very rarely will there be problems with tolerance or auto-immunity." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Cancer by sharing your contact details with the study coordinator.